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Abstract 
Background: Emerging data indicates that extracellular traps (ETs), structures formed by various immune cell types, 
may contribute to the pathology of noninfectious inflammatory diseases. Histone hypercitrullination is an important 
step in ETs formation and citrullinated histone H3 (H3cit) is considered a novel and specific biomarker of that process. 
In the present study we have evaluated circulating H3cit in stable asthmatics and investigated its relationship with 
asthma severity, pulmonary function and selected blood and bronchoalveolar lavage (BAL) biomarkers.
Methods: In 60 white adult stable asthmatics and 50 well‑matched controls we measured serum levels of H3cit. In 
asthmatics we also performed bronchoscopy with BAL. We analyzed blood and BAL biomarkers, including interleukin 
(IL)‑4, IL‑5, IL‑6, IL‑10, IL‑12p70, IL‑17A and interferon γ. For statistical analysis, Mann–Whitney U‑test, χ2 test, one‑way 
ANCOVA, ROC curve analysis and univariate linear regression were applied. Independent determinants of H3cit were 
established in a multiple linear regression model.
Results: Asthma was characterized by elevated circulating H3cit (17.49 [11.25–22.58] vs. 13.66 [8.66–18.87] ng/ml, 
p = 0.03). In asthmatics positive associations were demonstrated between serum H3cit and lung function variables, 
including total lung capacity (TLC) (β = 0.37 [95% CI 0.24–0.50]) and residual volume (β = 0.38 [95% CI 0.25–0.51]). 
H3cit was increased in asthma patients receiving systemic steroids (p = 0.02), as well as in subjects with BAL eosino‑
philia above 144 cells/ml (p = 0.02). In asthmatics, but not in controls, circulating H3cit correlated well with number 
of neutrophils (β = 0.31 [95% CI 0.19–0.44]) and monocytes (β = 0.42 [95% CI 0.29–0.55]) in peripheral blood. Further‑
more, BAL macrophages, BAL neutrophils, TLC, high‑sensitivity C‑reactive protein, Il‑12p70 and bronchial obstruction 
degree were independent determinants of H3cit in a multivariate linear regression model.
Conclusions: Asthma is characterized by increased circulating H3cit likely related to the enhanced lung ETs forma‑
tion. Inhibition of ETs might be a therapeutic option in selected asthma phenotypes, such as neutrophilic asthma.
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Introduction
Asthma is a common chronic inflammatory disease of 
the airways with a complex pathomechanism involv-
ing diverse immune processes [1, 2] accompanied by a 
low-grade persistent systemic inflammation [3]. Emerg-
ing data indicate that extracellular traps (ETs) may con-
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diseases [4–6]. ETs are web-like structures coated with 
histones, granular and cytosolic proteins, formed by vari-
ous immune cells, including neutrophils, eosinophils, and 
macrophages [7]. Neutrophil ETs (NETs) were first dis-
covered as being mainly implicated in the innate immune 
response in host defense, enabling neutrophils to immo-
bilize and kill invading bacteria, fungi or even viruses [6, 
8]. The impact and presence of ETs formation in asthma 
have not been extensively studied yet, however, previous 
studies suggest that NETs [9, 10] and eosinophil extracel-
lular traps (EETs) [4, 11] may contribute to the persistent 
airway inflammation in asthma. Moreover, Toussaint 
et  al. [12] have shown that rhinovirus respiratory tract 
infection, the most common cause of asthma exacerba-
tion in humans, induces host-derived double strand DNA 
release in nasal lavage samples of patients with mild-
moderate asthma.
There is also a growing body of evidence that ETs may 
be entangled in clotting of the blood. We have recently 
reported evidence of a prothrombotic state in asthma 
which is characterized by enhanced plasma thrombin 
formation, impaired clot lysis and platelet activation [13], 
all of them related to the low-grade systemic inflammation 
[3], endothelial injury [14], elevated exacerbation rate 
[15], and likely increased atherosclerotic risk [16, 17]. 
Higher risk of thromboembolic events in asthmatics 
has been also demonstrated in epidemiological studies 
[18–22]. The mechanisms functionally underlying this 
phenomenon are currently under investigation; however, 
ETs contribution may be of importance.
One of the key steps in ETs formation is citrullination 
of histones performed by the histone-specific enzyme 
peptidylarginine deiminase 4 (PAD4) [8]. Emerging 
data indicates that citrullinated histone H3 (H3cit), a 
key component of ETs, may be recognized as a specific 
marker of ETs formation both in tissue samples [23–25] 
and in peripheral blood [26–29]. Taking into account 
low-grade systemic inflammation demonstrated in 
asthma and important role of ETs formation in human 
pathology, we sought to evaluate serum H3cit, a 
specific biomarker of ETs formation, in asthma. We also 
studied its relation to asthma severity, lung function 




The study was conducted in the Department of Internal 
Medicine, Jagiellonian University Medical College, Kra-
kow, Poland, from June 2015 to January 2018. We enrolled 
60 white adult patients with clinically stable asthma 
according to the Global Initiative for Asthma (GINA) 
guidelines [30] and 50 well-matched controls. The study 
participants were 18–65  years old. Diagnosis of asthma 
was established based on a history of recurrent respira-
tory symptoms (wheeze, cough, shortness of breath, and 
chest tightness) together with current and/or histori-
cally documented postbronchodilator increase in forced 
expiratory volume in one second  (FEV1) of 12% and at 
least 200  ml from the baseline [30]. Atopic status was 
confirmed by a positive skin prick testing for at least one 
inhaled allergen (Allergopharma, Reinbeck, Germany). 
All asthma medications, except for biological therapy, 
were permitted, including oral corticosteroids at a daily 
dose equivalent to ≤ 10  mg of prednisolone, only if the 
dose was unchanged for 3 consecutive months. Asthma 
patients were eligible if they had no exacerbation dur-
ing the preceding 6 months. Severity of asthma was cat-
egorized according to the GINA guidelines [30]. “Mild” 
asthma was defined as a mild persistent disease, treated 
with short acting β2-agonist on demand, with or without 
low daily dose of inhaled corticosteroids (ICS) (< 250 μg 
of fluticasone propionate [FP] [dry powder inhaler] or 
equivalent). “Moderate” asthma was defined as a mild 
persistent disease treated with a low (combined with 
long-acting β2-agonists) or medium dose of ICS (250–500 
μg of FP or equivalent). “Severe” asthma was defined as 
severe persistent disease despite using high daily dose of 
ICS (> 500 μg of FP or equivalent). Asthma symptom con-
trol was assessed based on result of Asthma Control Test 
(ACT). Scores 20–25 were classified as “well-controlled 
asthma”, 16–19 as “not well-controlled”, while 5–15 as 
“very poorly controlled asthma”. Spirometry and bronchial 
reversibility test with 400 μg of albuterol as well as post-
bronchodilator body plethysmography with assessment of 
residual volume (RV) and total lung capacity (TLC) were 
measured in all enrolled asthma patients according to the 
American Thoracic Society (ATS) standards [31], using 
a Jaeger MasterLab spirometer (Jaeger-Toennies GmbH; 
Hochberg, Germany). In asthma patients we also per-
formed bronchoscopy with bronchoalveolar lavage (BAL).
Exclusion criteria comprised any acute illness, con-
gestive heart failure, atrial fibrillation, coronary heart 
disease, hyper- or hypothyroidism, liver injury, chronic 
kidney disease (stage 3 or more), autoimmune disease, 
malignant neoplasm or medical history of thromboem-
bolism. In turn, arterial hypertension, diabetes mellitus, 
or hypercholesterolemia were allowed as comorbidities 
in subjects studied. Arterial hypertension was defined 
based on a history of hypertension (blood pres-
sure > 140/90 mmHg), or present antihypertensive treat-
ment. Diabetes mellitus was defined as the current use 
of insulin, or oral hypoglycemic medications, or fasting 
serum glucose > 7.0  mmol/l. Hypercholesterolemia was 
defined as serum total cholesterol > 5.2  mmol/l or pre-
vious diagnosis along with lipid-lowering treatment. 
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Ex-smokers were eligible for enrolment if they had 
stopped smoking at least 5 years before inclusion.
Controls
Control subjects were enrolled from the hospital person-
nel and its relatives. They were matched with patients 
according to age, sex, BMI, smoking status and internal 
medicine comorbidities. Subjects with history of allergic 
diseases or bronchial obstruction were excluded. Each 
control was individually matched with two patients con-
sidering the closest values of the matching criteria.
Bronchofiberoscopy
Bronchofiberoscopy  was performed in asthma subjects 
according to the ATS guidelines [32] using the BF 1T180 
bronchoscope (Olympus, USA) with local anesthesia 
(2% lidocaine) and mild sedation (0.05–0.1  mg fenta-
nyl and 2.5–5  mg midazolam, both intravenously). BAL 
was performed with 200 ml of normal saline applied into 
the right middle lobe bronchus. First 10  ml aliquot of 
obtained BAL fluid was discarded, while the next sample 
was used for investigation.
BAL cellularity analysis
The cytospin preparations (Thermo Scientific, Walth-
man, MA) were made from BAL fluid samples and 
stained with the May-Grunwald Giemsa dye. Percentages 
of inflammatory cells among 1000 cells in each prepara-
tion were counted (with exception of epithelial cells). 
Remaining BAL fluid was centrifuged 2000×g for 20 min 
at room temperature, supernatant was frozen in aliquots 
and stored at − 70 °C until analysis.
Laboratory investigations
Fasting blood samples were drawn from the antecubital 
vein between 8:00 and 11:00 A.M, using minimal 
stasis. Lipid profile, glucose, creatinine, urea, alanine 
aminotransferase, as well as complete blood cell and 
platelet count were assayed by routine laboratory 
techniques. Fibrinogen was determined with the Clauss 
method. High-sensitivity C-reactive protein (hsCRP) 
and immunoglobulin E (IgE) were measured by latex 
nephelometry (Siemens, Marburg, Germany). Blood 
samples were drawn into serum separation tube, 
centrifuged 2000×g for 20 min, at room temperature. The 
supernatant was frozen in aliquots and stored at − 70 °C 
until analysis.
High sensitivity immunoenzymatic assays were used 
to measure levels of interleukin(IL)-4, IL-5, IL-6, IL-10, 
IL-12p70, IL-17A, and interferon (INF)γ (eBiosciencea, 
Vienna, Austria, all) in serum and BAL fluid of asthmat-
ics and in serum of 25 (50%) controls.
Concentration of H3cit in serum was measured using 
ELISA kit developed by Cayman Chemicals (Ann Arbor, 
MI, USA). This assay employed a monoclonal antibody 
specific for histone H3 citrullinated at R2, R8, and R17 
(clone 11D3). The lower limit detection of the assay was 
0.1 ng/ml, the upper 31 ng/ml.
Statistical analysis
Analyses were carried out using Statistica software pack-
age version 12.5 (TIBCO Inc). The Shapiro–Wilk test has 
shown that continuous variables were non-normally dis-
tributed. They were reported here as median and inter-
quartile range and compared using the Mann–Whitney 
U-test. Categorical variables were given as percentages 
and compared by χ2 test with Yates’ correction, if applica-
ble. Age, sex, and body mass index (BMI) were considered 
as potential confounders for laboratory investigations. 
Therefore, the Box-Cox normality transformation was 
used and a one way covariance analysis (ANCOVA) was 
performed to adjust for confounding factors. To test for 
associations between two continuous variables univari-
ate linear regression model was applied with adjustment 
for sex, age, and BMI. Independent determinants of H3cit 
were established in a multiple linear regression model, 
built by a forward stepwise selection procedure, verified 
by F Snedecor’s statistics, with F > 1. The R2 was used as a 
measure of the variance. Cut-off points of BAL and blood 
biomarkers in relation to circulating H3cit levels were cal-
culated in asthmatics based on receiver operating charac-
teristic (ROC) curves. Moreover, to compare biomarkers 
between H3cit-high and H3cit-low asthma subjects the 
 75th percentile value of the circulating H3cit in asthma 
individuals has been taken into account. In each case of 
multiple comparisons Bonferroni correction has been 
applied and the nominal level of significance has been 
reduced proportional to the total number of all tests per-
formed in multiple comparisons procedure. Results were 
considered significant when the p value was less than 0.05.
Results
Patients and controls
Clinical and laboratory characteristics of subjects studied 
are given in Tables 1 and 2, respectively.
Among asthmatics 41 (68.3%) subjects had atopy, 
while 30 (50%) were characterized by severe disease 
according to GINA [30]. Severe asthma was an indica-
tion for the use of systemic corticosteroids in 17 patients 
(28.3%). Asthma individuals were characterized by 
increased serum levels of IL-6, IL-10 (Fig. 1b, c), alanine 
aminotransferase activity, as well as elevated mono-
cyte, eosinophil, lymphocyte, and total white blood cell 
(WBC) counts as compared to controls (Table 1). Results 
of laboratory BAL investigations are presented in Table 3. 
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As it has been demonstrated, IL-6 and IL-12p70 were 
above the detection threshold in the majority of asthma 
patients. In turn, concentrations of IL-4, IL-5, IL-17A, 
and IFNγ in BAL and blood, as well as IL-10 in BAL were 
below the detection threshold in the majority of subjects 
(Additional file 1: Tables S1 and S2). 
As expected, in asthma concentration of IL-6 in 
BAL was associated with BAL and blood neutrophilia 
(β = 0.51 [95% CI 0.41–0.6] and β = 0.41 [95% CI 0.31–
0.51], respectively).
Citrullinated histone H3 in peripheral blood
Circulating H3cit was significantly elevated in asthmat-
ics in comparison to control group (17.49 [11.25–22.58] 
vs. 13.66 [8.66–18.87] ng/ml, p = 0.03), also after adjust-
ment for potential confounders (p = 0.02) (Fig. 1a). Inter-
estingly, women with asthma had 17% lower H3cit than 
male patients (16.21 [10.96–20.86] vs. 19.48 [15.86–
30.97] ng/ml, p = 0.03). Also only in asthma we docu-
mented a negative association between H3cit and BMI 
(β = − 0.28 [95% CI − 0.4 to − 0.15]).
Serum H3cit was not related to the ACT score and 
did not differ among asthma severity subtypes, albeit it 
was significantly elevated in patients receiving systemic 
steroids (21.07 [15.9–32.0] vs 16.21 [10.52–20.27] ng/
ml, p = 0.02) and in those on antileukotriene medica-
tions (24.76 [17.28–29.83] vs 16.36 [11.11–19.90] ng/
ml, p = 0.04). Administration of other drugs, as well as 
comorbidities had no impact on that parameter.
Laboratory variables and circulating H3cit
In asthma, but not in controls, circulating H3cit 
remained in positive associations with number of mono-
cytes (β = 0.42 [95% CI 0.29–0.55]) and neutrophils 
Table 1 Clinical characteristics of subjects studied
Categorical variables are presented as numbers (percentages), continuous variables as median (interquartile range)
Asthma n = 60 Controls n = 50 p-value
Age, years 50 (39–56) 45.5 (39–53) NS
Female gender 44 (73.7) 29 (58.0) NS
Height, m 1.63 (1.58–1.71) 1.65 (1.6–1.76) NS
Body mass index (BMI), kg/m2 26.9 (23.4–31.6) 26.4 (23.0–28.1) NS
History of smoking 18 (30.0) 17 (34.0) NS
Active smokers 7 (11.7) 8 (16.0) NS
Arterial hypertension 27 (45.0) 16 (32.0) NS
Diabetes mellitus 8 (13.3) 5 (10.0) NS
Hypercholesterolemia 17 (28.3) 16 (32.0) NS
Medications used:
 Inhaled corticosteroids 59 (98.3)
 Long‑acting β2‑agonists 49 (81.7)
 Montelukast 9 (15.0)
 Oral corticosteroids 17 (28.3)
Atopy 41 (68.3)
Asthma duration, years 10 (5–15)
Asthma control (according to Asthma Control Test results)
 Well‑controlled (score > 19) 15 (25.0)
 very poorly controlled (score > 16) 25 (41.7)
Asthma severity (GINA):
 Mild 9 (15.0)
 Moderate 21 (35.0)
 Severe 30 (50.0)
Prebronchodilator  FEV1/VC, % 67.8 (59.4–75.9)
Postbronchodilator  FEV1/VC, % 73.1 (68.2–79.7)
Postbronchodilator TLC, L




[% of predicted value]
2.23 (1.67–2.66)
[123.6 (108.3–147.2)]
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Table 2 Peripheral blood basic laboratory results
Variables are presented as median and interquartile range
Asthma n = 60 Controls n = 50 p-svalue
White blood cells,  103/μl 6.82 (5.69–8.18) 5.73 (5.09–6.96) 0.003
Neutrophils,  103/μl 3.39 (2.80–4.35) 3.3 (3.0–3.45) NS
Eosinophils, 1/μl 285 (140–470) 150 (90–240) < 0.001
Monocytes,  103/μl 0.62 (0.50–0.88) 0.43 (0.40–0.49) < 0.001
Lymphocytes,  103/μl 2.04 (1.66–2.50) 1.69 (1.44–2.16) 0.02
Blood platelets,  103/μl 230 (194–265) 224 (203–269) NS
Hemoglobin, g/dl 13.0 (13.0–14.5) 13.8 (12.8–15.0) NS
C‑reactive protein, mg/l 1.64 (0.51–6.63) 1.02 (0.91–3.33) NS
IgE, IU/ml 152.0 (34.1–532.0) 30.0 (17.8–37.0) 0.01
Alanine aminotransferase, IU/l 28 (22–42) 22 (14–28) < 0.001
Total cholesterol, mmol/l 4.9 (4.1–5.6) 4.7 (4.1–5.2) NS
Low density lipoprotein cholesterol, mmol/l 2.6 (1.9–3.1) 2.98 (2.48–3.51) 0.02
High density lipoprotein cholesterol, mmol/l 1.3 (1.1–1.6) 1.51 (1.25–1.84) NS
Triglycerides, mmol/l 1.4 (1.2–2.0) 0.9 (0.7–1.4) 0.003
Fig. 1 Circulating H3cit and relevant serum cytokine concentrations in asthma and control subjects. * Median value. ** Results available in 25 
(50%) of control subjects. Serum H3cit was above the limit of detection (LoD) in all subjects studied (a). Serum IL‑6 was above the LoD in 56 (93.3%) 
asthmatics and 18 controls (b). Serum IL‑10 was above the LoD in 51 (85.0%) asthmatics and 14 controls (c). Serum IL‑12p70 was above the LoD in 
27 (45.0%) asthmatics and 7 controls (d)
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(β = 0.31 [95% CI 0.19–0.44]) in peripheral blood (Fig. 2). 
Interestingly, in the patient group it also correlated with 
number of macrophages in BAL (β = 0.27 [95% CI 0.14–
0.4]). Asthma patients with higher H3cit, defined as a 
value above 22.58  ng/ml (75th percentile in asthmatics) 
were characterized by increased monocyte (880 [680–
1080] vs. 550 [480–720] cells/μl; p = 0.0009) and neu-
trophil (4350 [3730–7000] vs. 3120 [2580–3740] cells/μl; 
p = 0.0005) cell count in peripheral blood.
Moreover, using ROC curve analysis to calculate cut-
off points we found that serum H3cit was increased 
in subjects with BAL eosinophilia above 144 cells/
ml (20.77 [18.26–23.27] ng/ml vs. 16.05 [14.57–17.54] 
ng/ml, p = 0.02), with BAL total cell count higher than 
10.725  cells/ml (18.09 [11.29–29.83] ng/ml vs. 15.12 
[9.48–19.53] ng/ml, p = 0.03), as well as with BAL IL-6 
levels higher than 0.76 pg/ml (19.53 [11.29–32.00] ng/
ml vs. 15.98 [10.96–18.06] ng/ml, p = 0.04) (Additional 
file  2: Fig.  S1). Interestingly, in controls H3cit was 
directly associated with serum IL-6 (β = 0.33 [95% CI 
0.1–0.56]).
Lung function tests and circulating H3cit
In asthmatics, serum H3cit was strongly related to the 
results of lung function tests, including TLC (β = 0.37 
[95% CI 0.24–0.50]) and RV (β = 0.38 [95% CI 0.25 to 
0.51]), also after adjustment for potential confounders. 
Asthma patients with higher H3cit, defined as values 
above 22.58 ng/ml (75th percentile as the cut-off point) 
had higher TLC in comparison to the remainders (6.42 
[5.82–7.33] vs. 5.55 [5.11–6.14]; p = 0.007) (Additional 
file 3: Fig. S2c). Moreover, a weak negative relationship 
Fig. 2 Correlations between peripheral blood cell counts and serum H3cit concentration. a–c Present correlations in asthma patients. d–f Present 
correlations in controls. Pearsons’s correlation coefficients with p‑values were calculated and are shown in the panels
Table 3 Results of BAL investigations in asthmatics
Variables are presented as median and interquartile range
BAL cellularity
 Macrophages, number of cells per 1 ml 8763 (5697–16,119)
 Lymphocytes, number of cells per 1 ml 943 (561–1969)
 Neutrophils, number of cells per 1 ml 297 (187–497)
 Eosinophils, number of cells per 1 ml 80 (8–196)
BAL fluid cytokines
 IL‑6, pg/ml 0.736 (0.153–1.116), above the LoD in 47 (78.3%) 
subjects
 IL‑12 (p70), pg/ml 0.081 (0.052–0.118), above the LoD in 58 (96.7%) 
subjects
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was demonstrated between H3cit and prebronchodila-
tor  FEV1/vital capacity (VC) index (β = −0.19 [95% CI 
− 0.32 to − 0.07]).
Multiple regression model to predict circulating H3cit
Independent determinants of circulating H3cit in asth-
matics were identified using forward stepwise selection 
procedure. The number of macrophages and neutrophils 
in BAL, hsCRP, TLC, and the degree of prebronchodila-
tor airway obstruction were demonstrated as positive 
predictors of H3cit level in peripheral blood. In turn, sur-
prisingly, IL-12 (p70) had a negative impact on circulat-
ing H3cit in that analysis. All aforementioned variables 
explained 57% of H3cit variability (Table 4).
Discussion
In the present study we have demonstrated that serum 
H3cit, a novel biomarker of ETs formation, is increased 
in stable asthma subjects. Although serum H3cit was not 
related to the asthma severity according to the GINA 
guidelines, a weak negative correlation with  FEV1/VC 
suggests that enhanced bronchial obstruction, charac-
teristic for more severe asthma subtype, might be associ-
ated with ETs release. The same applies to the tendency 
towards elevated circulating H3cit in those on systemic 
steroids or even anti-leukotriene medications. To our 
knowledge there is no evidence for upregulation of ETs 
formation by steroids [33] or leukotriene antagonists, 
however we cannot exclude such a relationship.
Previously, Dworski et al. [11] have found evidence for 
lung EETs and NETs formation in endobronchial biopsy 
specimens of mild and well-controlled asthma patients. 
In our study, the positive correlations demonstrated for 
TLC or RV and circulating H3cit suggest that indeed, 
lungs might be the site of ongoing ETs formation with 
subsequent H3cit release into the peripheral blood of sta-
ble asthmatics. It might be assumed that in asthma higher 
lung volume and capacity, thus larger inflammatory site 
area, might result in the increase of local ETs generation.
Interestingly, in asthma serum H3cit was related to 
the number of monocytes and neutrophils in peripheral 
blood, as well as macrophages in BAL. It is an intrigu-
ing result, as the issue of extracellular trap formation by 
macrophages remains a subject of ongoing research and 
debate [34]. On the other hand, we found no direct asso-
ciation between serum H3cit and number of neutrophils 
in BAL. That finding might be to some extent explained 
by the relatively low percentage of patients with neutro-
philic BAL in our cohort, as other studies demonstrated 
increased NETs in neutrophilic asthma sputum [10]. 
However, we found increased H3cit among asthmatics 
with higher BAL eosinophilia. Previously, Choi et al. [4] 
have demonstrated likely impact of eosinophils’ derived 
EETs on airway inflammation. Our results stay in line 
with their finding, although BAL composition does not 
necessarily reflect lung tissue inflammation [11].
Associations between circulating H3cit and blood 
monocytes or neutrophils were not directly documented 
in the multivariate linear regression model, as hsCRP, a 
biomarker closely related to monocyte and neutrophil 
counts in our study (data not shown), was a more precise 
determinant of serum H3cit. Moreover, in that model 
BAL macrophages and BAL neutrophils remained 
independent H3cit determinants, suggesting the role of 
H3cit as a potential biomarker of neutrophilic asthma 
even despite the lack of a direct correlation between BAL 
neutrophils and H3cit.
Interestingly, in our asthma cohort higher concentra-
tions of BAL IL-6 was associated with increased circulat-
ing H3cit. In turn, elevated serum IL-6 in asthmatics stays 
in line with the previous reports of persistent low-grade 
systemic inflammation in asthma. Links between NETs 
and cytokine release have already been documented, e.g. 
NETs may induce the transcription of IL-6 and pro-IL-1β 
genes in macrophages in early atherosclerosis [8]. Sur-
prisingly, in our study asthma patients were character-
ized by IL-10 elevation as compared to controls. IL-10 is 
rather known for its anti-inflammatory properties includ-
ing inhibition of NETs release [8]. Moreover, Borish et al. 
have found diminished IL-10 BAL fluid concentrations in 
asthmatics [35]. However, the observed increase in serum 
IL-10 in our study together with the negative correlation 
between BMI and H3cit in asthma subjects make further 
research of interactions between cytokines, adiponectin 
and ETs release of interest.
Interestingly, serum H3cit was negatively determined 
by serum IL-12(p70), a major player in the initiation and 
maintenance of T helper 1 cells response [36]. IL-12 is 
Table 4 Independent determinants of  circulating H3cit 
in asthmatics
The resulting standardized regression coefficient (β) with 95% confidence 
intervals (95% CI) for a factor (independent variable) indicates the increase/
decrease in standard deviations (SDs) of dependent variable, when that 
particular factor increases with 1 SD and all other variables in the model are 
unchanged
β 95% CI
FEV1/VC,  % − 0.15 − 0.28 to − 0.03
TLC, L 0.41 0.28 to 0.54
Macrophages, number per 1 ml of BAL fluid 0.21 0.07 to 0.34
Neutrophils, number per 1 ml of BAL fluid 0.36 0.24 to 0.50
IL‑12(p70) in serum, pg/ml − 0.18 − 0.32 to − 0.05
hsCRP, mg/l 0.37 0.22 to 0.51
F = 6.65,  R2 = 0.58, p = 0.0002
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known to inhibit airway inflammation and bronchial 
obstruction in murine models of allergic asthma [37]. 
An interventional study with recombinant IL-12 in 
human asthmatics showed a decrease in peripheral 
blood and sputum eosinophilia with no impact on 
bronchial reactivity [38]. Another function of IL-12 is 
the inhibition of pathological angiogenesis [39]. It has 
been demonstrated that abnormal neovascularization 
is an important feature of airway remodeling in asthma 
patients [40, 41]. We cannot exclude, that in asthmatics 
with enhanced ETs formation decrease of IL-12 might 
contribute to the unfavorable airway remodeling and 
bronchial neovascularization.
Notably, increased H3cit in peripheral blood of asthma 
subjects is particularly important, since there is a grow-
ing body of evidence that enhanced ETs formation might 
contribute to the development of various systemic seque-
lae, including thrombotic complications or autoimmun-
ity [6] [51]. In particular, the presence of autoantibodies 
against citrullinated peptides in rheumatoid arthritis, 
another noninfectious inflammatory disease, is likely 
related to the PAD4 activity enabling ETs release [6, 42]. 
In turn, severe asthma patients present more frequently 
with autoimmune diseases [52]. Thus, production of ETs 
with subsequent release of related products into the cir-
culation may provide the initial stimulus for autoimmun-
ity, explaining the increased rate of autoimmune diseases 
in asthmatics.
Moreover, it has been demonstrated that histones 
might directly contribute to inflammatory injury by a 
host tissue damage [43–46], including microvascular 
endothelial barrier disruption and subsequent cell inflow 
into the inflammatory site [43, 47, 48]. Experimental 
approach with specific H3cit inhibition led to improved 
outcomes in mouse sepsis models [29, 49]. Although this 
is only a hypothesis, we believe that even relatively low 
concentrations of H3cit and other citrullinated histone 
types may contribute to the endothelium damage in 
asthmatics. The availability of pharmacologic histone 
inhibitors makes it a particularly intriguing issue, as 
their use might be of benefit at least in some asthma 
phenotypes.
Furthermore, the potential contribution of ETs for-
mation to the prothrombotic phenomenon in asthma 
also deserves a comment. Fuchs et al. [50] has reported 
that NETs trigger the blood clotting through activa-
tion of platelets, recruitment of red blood cells and 
stimulation of fibrin deposition, being a potential link 
between immune response and thrombosis. In par-
ticular, Ammollo et  al. [51] revealed that extracellular 
histones increase plasma thrombin generation by impair-
ing thrombomodulin-dependent protein C activation. 
Recently, Zuo et  al. [52] documented increased H3cit 
and myeloperoxidase-DNA (MPO-DNA) in sera of sub-
jects with coronavirus disease 2019 (COVID-19), illness 
accompanied by clotting impairment and microvascular 
thrombosis. Thus, we speculate that elevated circulating 
H3cit may, at least to some extent, explain prothrombotic 
blood alterations and increased risk of thromboembolic 
complications demonstrated even in well-controlled 
asthma patients [13, 18–20].
The limitations of our study include relatively small 
sample size. Particularly, subgroup analysis should be 
interpreted with caution. We determined each variable 
at a single time point, thus we cannot exclude changes 
of the variables during time. We did not analyze ETs 
formation in a functional assay. However, the laboratory 
techniques for directly determining the ETs formation 
are difficult and very demanding from the technical point 
of view. Applied here H3cit ELISA assay is simple, but 
relatively novel, thus might require further validation 
before being established as a reliable test for the extensive 
use in practice. We analyzed H3cit in blood and not in 
airways, which are the main loci of asthma inflammatory 
response. We did not measure other cytokines potentially 
relevant for the lung and systemic inflammatory 
response, including IL-1β and IL-18, released after 
NLRP3 stimulation by NETs [53]. Statistical associations 
reported here might not necessarily indicate cause-effect 
relationships. Finally, a clinical relevance of increased 
serum H3cit in relation to asthma course, disease 
progression, exacerbation risk, or vascular outcomes 
remains to be established.
Conclusion
Asthma is characterized by increased circulating H3cit 
likely related to the enhanced lung ETs formation. 
Although large experimental and observational 
studies are needed to verify this hypothesis, it seems 
that ETs release is involved in asthma pathogenesis. 
Thus inhibition of ETs might be a therapeutic option 
in selected asthma phenotypes, such as neutrophilic 
asthma.
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